Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients

Ogunkeye, O.O.; Chuhwak, EK; Otokwula, Abraham A.

doi:10.1016/j.pathophys.2009.05.003

Cited by 12 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data of M.G Khan, study conducted that 100% patients with cirrhosis had lower serum cholinesterase level and he also showed that there was close relationship between the severity of cirrhosis and the level of serum cholinesterase [20]. Another study of O. Ogunkeye et al also evaluated the low serum cholinesterase level in liver disease patients [21]. Our study also correlates with various studies of scientists who evaluate that Serum cholinesterase values were lowered in all liver disease patients.…”

Section: Discussionsupporting

confidence: 83%

‘Role of Serum Cholinesterase and 5-Nucleotidase Enzyme Activity in the Diagnosis of Alcoholic and Non-Alcoholic Liver Disease and Compared With Healthy Subjects of Rajasthan’

Vyas¹,

Vyas²,

Sharma³

2019

SJMPS

View full text Add to dashboard Cite

Aim of the study was to find out the role of biochemical markers in diagnosis of alcoholic liver disease and non-alcoholic liver disease and compared these values with healthy subjects of Rajasthan. Total 300 subjects were selected in which 200 were selected as patients group (alcoholic liver disease (ALD) and non-alcoholic liver disease (NALD) group) and 100 were normal healthy subjects. Total 100 alcoholic liver disease patients in which 91 patients were male and 09 patients were female. In non-alcoholic liver disease group 55 males and 45 females are enrolled. Patients were distributed age wise. Serum cholinesterase and serum 5-nucleotidase were estimated by commercially available kit on spectrophotometer. Serum cholinesterase level is 2822.99± 716.51 in ALD patients. In NALD patients, serum cholinesterase level was 4299.95±1014.76 and in control group mean serum cholinesterase level was 6303.99±977.59. Pvalue was statically highly significant. (P≤ 0.0001), as well as serum 5-nucleotidase level was 25.89± 5.77 and 17.70± 4.43 in ALD and NALD respectively. In control group mean level of serum 5-nucleotidase was 9.851± 3.24. (P≤ 0.0001). We conclude that serum cholinesterase level was decreased in both disease group, whereas serum 5-nucleotidase level is increased in both disease groups. Both parameters are liver specific and specific test for alcohol induced or alcoholic liver disease as well as in non-alcoholic liver disease. Both parameters can be used as a marker of liver disease. it was concluded that serum cholinesterase and 5'-nucleotidase are better diagnostic marker then the conventional liver function test that are raised in other liver disease also.

show abstract

Section: Discussionsupporting

confidence: 83%

‘Role of Serum Cholinesterase and 5-Nucleotidase Enzyme Activity in the Diagnosis of Alcoholic and Non-Alcoholic Liver Disease and Compared With Healthy Subjects of Rajasthan’

Vyas¹,

Vyas²,

Sharma³

2019

SJMPS

View full text Add to dashboard Cite

show abstract

“…Because parasympathetic activity tends to attenuate the secretion of VLDL‐TG and increase the stores of TG in the liver [18,29], and serum cholinesterase activity is elevated in human fatty liver disease [31,32], AChE inhibitors may have some influence on hepatic lipid metabolism. In the present study, administration of the AChE inhibitor physostigmine did not induce the accumulation of TG in normal liver from mice fed ad libitum, but did exacerbate the accumulation of TG in the fatty liver caused by 30 h of fasting.…”

Section: Discussionmentioning

confidence: 99%

Acetylcholinesterase (AChE) inhibition aggravates fasting‐induced triglyceride accumulation in the mouse liver

Yokota¹,

Nakamura²,

Ando³

et al. 2014

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…In contrast, a study of DM patients with or without NAFLD found decreased cholinesterase activity in those with hepatic steatosis. 141 Cholinesterase activity may have been elevated at earlier stages of the disease and only had decreased activity in cases with advanced liver cell damage, which may explain the controversial results. This fact indicates that cholinesterase activity may also serve as an indicator of the severity of steatosis.…”

Section: Potential Biomarkers Of Novel Liver Fat Indicesmentioning

confidence: 99%

Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies

Reinshagen¹,

Kabisch²,

Pfeiffer³

et al. 2023

J Clin Transl Hepatol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with the metabolic syndrome and type 2 diabetes and independently contributes to long-term complications. Being often asymptomatic but reversible, it would require population-wide screening, but direct diagnostics are either too invasive (liver biopsy), costly (MRI) or depending on the examiner’s expertise (ultrasonography). Hepatosteatosis is usually accommodated by features of the metabolic syndrome (e.g. obesity, disturbances in triglyceride and glucose metabolism), and signs of hepatocellular damage, all of which are reflected by biomarkers, which poorly predict NAFLD as single item, but provide a cheap diagnostic alternative when integrated into composite liver fat indices. Fatty liver index, NAFLD LFS, and hepatic steatosis index are common and accurate indices for NAFLD prediction, but show limited accuracy for liver fat quantification. Other indices are rarely used. Hepatic fibrosis scores are commonly used in clinical practice, but their mandatory reflection of fibrotic reorganization, hepatic injury or systemic sequelae reduces sensitivity for the diagnosis of simple steatosis. Diet-induced liver fat changes are poorly reflected by liver fat indices, depending on the intervention and its specific impact of weight loss on NAFLD. This limited validity in longitudinal settings stimulates research for new equations. Adipokines, hepatokines, markers of cellular integrity, genetic variants but also simple and inexpensive routine parameters might be potential components. Currently, liver fat indices lack precision for NAFLD prediction or monitoring in individual patients, but in large cohorts they may substitute nonexistent imaging data and serve as a compound biomarker of metabolic syndrome and its cardiometabolic sequelae.

show abstract

Serum cholinesterase activity in the diagnosis of nonalcoholic fatty liver disease in type 2 diabetic patients

Cited by 12 publications

References 15 publications

‘Role of Serum Cholinesterase and 5-Nucleotidase Enzyme Activity in the Diagnosis of Alcoholic and Non-Alcoholic Liver Disease and Compared With Healthy Subjects of Rajasthan’

‘Role of Serum Cholinesterase and 5-Nucleotidase Enzyme Activity in the Diagnosis of Alcoholic and Non-Alcoholic Liver Disease and Compared With Healthy Subjects of Rajasthan’

Acetylcholinesterase (AChE) inhibition aggravates fasting‐induced triglyceride accumulation in the mouse liver

Liver Fat Scores for Noninvasive Diagnosis and Monitoring of Nonalcoholic Fatty Liver Disease in Epidemiological and Clinical Studies

Contact Info

Product

Resources

About